Abstract: Compositions and methods for modified viral vectors which mitigate the immunogenicity of viral vectors, enabling multiple administrations of viral-based gene delivery viral vectors are described herein. The viral vectors advantageously possess low immunogenicity and comprise at least one immunosuppressive moiety. Also described herein are methods for introducing genetic material into a cell. Additionally, described herein are methods for preparing a modified viral vector. Lastly, described herein are methods for treating a subject, the method comprising administering to a subject a modified viral vector composition as described above.

Abstract: N-oxide and monomers, N-oxide polymers and copolymers, methods for making the N-oxide monomers, polymers, and copolymers, compositions and materials that include N-oxide polymers and copolymers, and methods for using the N-oxide monomers, N-oxide polymers, and N-oxide copolymers.

Abstract: An airborne device which has a bus interface and a dedicated wireless transmission apparatus connected to the bus interface, the dedicated wireless transmission apparatus includes: an interface conversion module; and a wireless transmission module. The interface conversion module is configured to convert bus data received from the bus interface into a data packet suitable for transmission using a radio access technology, and/or to convert a data packet received from the wireless transmission module into bus data corresponding to the bus interface. The wireless transmission module is configured to use the radio access technology to transmit the converted data packet, and/or to receive the data packet transmitted using the radio access technology. In addition, a method and a system for wireless interconnection between airborne devices.

Abstract: Embodiments of the present invention disclose a logic intelligent control system of train door based on intelligent control unit. The system comprises: a first intelligent control unit located in a selected vehicle of a train, a second intelligent control unit located in each of the other remaining vehicles of the train, and a door controller located in each vehicle. The first intelligent control unit is configured to output corresponding door control instructions through the corresponding door control instruction output port after acquiring door control operation information; the door control instruction input ports corresponding to the first intelligent control unit and the second intelligent control units are configured to drive corresponding door controller control ports to control the door controllers of a corresponding vehicle to execute the door control instruction after receiving the door control instructions.

Abstract: Methods for characterizing DNA impurities in adeno-associated virus (AAV) samples or biopharmaceuticals are provided including the use of size exclusion chromatography and spectrophotometry. Methods and compositions are also provided to minimize leakage of packed DNA from AAV vector including the use of excipients, such as a sugar, an amino acid, a surfactant, or polyols.

Abstract: Methods and systems for identifying capsid viral proteins in a sample containing viral vectors are provided, including determining the ratio of the capsid viral proteins of adeno-associated virus. The methods and systems comprise denaturing the capsid viral proteins in the sample, labeling the denatured capsid viral proteins with a lysine-conjugation dye, generating a separation profile of the denatured/labeled capsid viral proteins using microchip capillary electrophoresis, quantifying levels of the capsid viral proteins based on the separation profile, determining a quantification ratio of the capsid viral proteins based on the separation profile, and normalizing the quantification ratio based on lysine contents of the capsid viral proteins.

Abstract: A delivery system that allows for targeted released of therapeutics in selected regions of the GI tract is provided. The delivery system is adapted to deliver a certain type of therapeutic, such as a protein-based therapeutic, to a certain area of the GI tract, such the colon of a subject. The delivery vehicle comprises a microbead coated with layers that include: a subcoat layer and a therapeutic agent layer. The delivery vehicles may also include an enteric coating layer and/or a sustained release layer.